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Abstract
Introduction: Refractory ulcerative colitis has a high, unmet medical need for avoiding steroid dependency and avoiding colectomy.
Controlled trials with biologic agents have recently been reported.
Aims: We aimed to review the current evidence supporting the use of the monoclonal antitumor necrosis factor antibody, infliximab, in
active ulcerative colitis and determine its current place in therapy. 
Evidence review: Although faced with initial conflicting data particularly in steroid-refractory patients, two large, placebo-controlled
trials have shown that intravenous infliximab induces and maintains clinical improvement in a clinically significant proportion of patients
when used with scheduled re-treatment. Infliximab also spares steroids and induces endoscopic remission in moderately ill patients. In
fulminant colitis unresponsive to intravenous steroids, one placebo-controlled trial indicates that infliximab is able to prevent colectomy
in this patient population. Evidence for cost effectiveness and avoidance of colectomy long term are still lacking.
Place in therapy: Infliximab 5 mg/kg induction at 0, 2, and 6 weeks, and every 8 weeks thereafter should be considered in patients with
moderately to severely active ulcerative colitis failing medical therapy. Steroid-dependent and steroid-refractory patients also qualify for
infliximab therapy.
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Core evidence place in therapy summary for infliximab in moderate to severe ulcerative colitis
Outcome measure Evidence Implications
Patient-oriented evidence
Improvement of symptoms Clear Improved disease control
Maintenance of clinical response  Clear Improved disease control long term
Sparing of steroids Clear Prevention of steroid-induced complications in corticodependent patients
Prevention of colectomy Moderate Substantial evidence on short-term efficacy; long-term data awaited
Improvement in quality of life Limited Reduced hospitalizations 
Efficacy superior to steroids Limited No controlled comparative trials available; uncontrolled trials suggesting
equivalence
Disease-oriented evidence
Endoscopic healing of mucosal lesions Clear Biologic endpoint reflecting reduced colonic inflammation and increased
mucosal repair
Induction of T-cell apoptosis No evidence Apoptosis induction as a mechanism of action for biologics has not been
established in ulcerative colitis
Prevention of colonic dysplasia No evidence Mucosal healing is associated with a decreased risk of dysplasia, but no
data are available for infliximab
Economic evidence
Cost effectiveness as an alternative to corticosteroid therapy No evidence Long-term pharmacoeconomic studies missing
Cost effectiveness as an alternative to calcineurin inhibitors or
colectomy in fulminant colitis
No evidence Long-term colectomy avoidance data missingScope, aims, and objectives
Despite the therapeutic efficacy of the biologic agent infliximab
(Remicade®) in Crohn’s disease, the development of agents
specifically interacting with an immune pathway has not led to
registered novel therapeutics in ulcerative colitis (UC). Recently
more biologic agents have entered development programs in
this indication but contrary to the situation in Crohn’s disease,
many of these programs have originally been driven by interest
from investigators involved in patient care and not by the
pharmaceutical industry. Several reasons may underlie this
discrepancy in “market interest” between Crohn’s disease and
UC. First, the immunopathogenesis of UC is ill-defined and this
hinders the selection of a clear target pathway. The lack of
paradigm about cytokines driving the inflammatory reaction in
UC prevents extrapolation to other diseases such as
rheumatoid arthritis, spondyloarthropathy, or psoriasis, as is
the case for Crohn’s disease. Finally, colectomy with ileal pouch
anastomosis is viewed by many as a good solution for
refractory UC even with all the possible long-term
inconveniences associated with this procedure. 
Although the pathogenesis of UC is incompletely understood,
several lines of evidence justify the development of antitumor
necrosis factor (anti-TNF) agents in the medical management 
of UC. Until 2 years ago, most of the data had originated 
from uncontrolled studies, but three large, placebo-
controlled trials have recently demonstrated that for moderate
to severe UC and for fulminant steroid-refractory UC, the anti-
TNF agent infliximab has clinical efficacy. This review will
discuss the scientific rationale for using anti-TNF agents in UC
and will address the current evidence supporting a role for
infliximab in inducing and maintaining clinical improvement in
active UC.
Methods
English language literature searches were conducted in the
following databases, searching from the beginning of the
database to date unless otherwise stated. The search strategy
was “infliximab AND ulcerative colitis” unless otherwise stated
(Table 1):
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 
• Web of Science, http://scientific.thomson.com/products/wos
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm
Disease overview
Inflammatory bowel diseases (IBD) are chronically relapsing
intestinal inflammatory conditions with a typical onset in young
adulthood and with an unpredictable disease course that may
lead to debilitating complications. Crohn’s disease and UC are
the two main phenotypes of IBD. These chronic immune-
mediated disorders are characterized by abdominal symptoms
(diarrhea, abdominal pain, rectal bleeding) and systemic
manifestations (arthralgia, fatigue, dermatologic and biliary
complications). The most pertinent difference between the two
illnesses is the disease location. Crohn’s disease typically
occurs in the terminal ileum (terminal enteritis) and right-sided
colon. However, lesions can appear anywhere in the gut and
the disease frequently affects different parts of the intestine
with skip areas of uninvolved mucosa (regional enteritis). UC,
on the other hand, most often involves the rectum and extends
over a variable distance in the colon. Two-thirds of patients
have only left-sided colonic disease with sparing of the right
colon. Also, Crohn’s disease is a transmural disease leading to
fistulas and intestinal strictures, whereas UC only affects the
colonic mucosa and submucosa. 
While UC can present at any age, patients are often diagnosed
in young adulthood, which means that this disease is
associated with a high psychologic and socioeconomic burden.
The diagnosis is based on the clinical presentation, on 
findings at colonoscopy, and on histologic findings in mucosal
biopsies. The course of UC is notably unpredictable at
diagnosis. Some patients have smoldering disease with few
symptoms and occasional flares, but others have signs of
severe systemic inflammation and debilitating diarrhea with
abdominal cramps, necessitating aggressive medical
management. Fifteen to twenty percent of patients will develop
fulminant colitis necessitating hospitalization and intravenous
therapy during the course of their disease. Complications
include toxic megacolon, profuse colonic bleeding, and
colorectal cancer.
UC is relatively infrequent with an estimated incidence of five
per 100 000 in the US, Canada, Australia, South Africa, and
northwestern Europe. Latin and South America, southern
Europe, and the rest of the world appear to have a much lower
incidence. However, since UC is a lifetime illness, peak
prevalences of one in 500 have been reported. At present most
patients need to be treated long term (several decades).
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Category Number of records
Full papers Abstracts
Initial search 268 0
records excluded 243
records included 25
Additional studies identified 32 1
Total records included 57 1
Level 1 clinical evidence
(systematic review, meta analysis)
1 0
Level 2 clinical evidence (RCT) 5 1
Level ≥3 clinical evidence 20 1
Economic evidence 0 0
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website. 
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review 153
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Role of TNF in the pathogenesis of UC
Although UC, like Crohn’s disease, is a chronic inflammatory
disorder of unknown origin, some elements in the cascade driving
the inflammatory reaction and the tissue damage in the colonic
mucosa and submucosa have been elucidated. In contrast to
Crohn’s disease, which is characterized by a predominant 
T-helper-1 cytokine profile with secretion of cytokines such as
interleukin-2 (IL-2) and interferon-gamma (IFN-gamma), the
uncontrolled tissue damage in the mucosa and submucosa of UC
patients appears to be fostered by humoral immunity with
antibody-secreting plasma, T lymphocytes with a T-helper-
2 cytokine profile, and neutrophils. Plasma cells isolated from the
gut wall of UC patients produce copious amounts of
immunoglobulin G (IgG) and complement-activating IgG1
antibodies are preferentially secreted (Halstensen et al. 1993).
Also, autoantibodies directed against endogenous proteins such
as tropomyosins are secreted in the serum of UC patients,
corroborating the role of humoral, B-cell-mediated immunity in
UC (Das et al. 1993). Despite these apparent differences in
lymphocyte subtypes driving the inflammatory reaction in Crohn’s
disease and UC, the effector phase of the immune response in
both types of IBD is characterized by the secretion of similar
inflammatory cytokines such as TNF and IL-1-beta. Indeed,
several lines of evidence support the development of anti-TNF
agents to treat patients with active UC. In inflamed mucosa, in the
serum, and in the stools of both Crohn’s disease and UC patients
the proinflammatory cytokines IL-1, IL-6, and TNF predominate.
More specifically, TNF immunoreactive cells are increased in the
lamina propria of UC and Crohn’s disease patients (Murch et al.
1993). This phenomenon is found in both adults and children with
IBD, although in children the TNF increase is particularly elevated
in Crohn’s disease (Murch et al. 1993; Breese et al. 1994).
Intraluminal TNF levels obtained by colonic lavage are increased
in active but not in endoscopically quiescent UC (Casellas et al.
1994). Serum TNF levels are markedly elevated in patients with
UC, and patients with active disease have a 1.7-fold higher level
than patients with inactive disease (Komatsu et al. 2001).
Furthermore, an imbalance in the secretion of TNF and
neutralizing soluble TNF receptors favoring the secretion of TNF
has been observed in culture supernatants of colonic biopsies
from patients with active colitis (Noguchi et al. 1998). Moreover,
the TNF-alfa converting enzyme (TACE), which serves to activate
and release TNF from the cell membrane, is specifically increased
in colonic biopsies of UC patients as compared to biopsies from
patients with Crohn’s disease or healthy individuals (Brynskov et
al. 2002). Indeed, in the cotton-top tamarin animal model of UC,
humanized anti-TNF antibodies ameliorate the spontaneous
colitis (Watkins et al. 1997). 
In Crohn’s disease a clear defect in apoptosis of lamina propria
and circulating T cells has been reported (Ina et al. 1999); also, in
UC, deficiencies in T-cell apoptosis have been observed
(Boirivant et al. 1999). Anti-TNF agents may act in IBD through the
induction of T-cell apoptosis or through restoration of defective
apoptosis rather than through simple neutralization of soluble or
membrane-bound TNF. In Crohn’s disease, ex-vivo and recently
also in-vivo evidence points to this hypothesis (Lügering et al.
2001; Van den Brande et al. 2003; Shen et al. 2007). In UC the
relative role of apoptosis induction relative to TNF neutralization
for the efficacy of anti-TNF antibodies needs further study.
Antimetabolite immunosuppressives such as azathioprine and 
6-mercaptopurine also may act by inducing T-cell apoptosis or by
inhibiting T-cell proliferation in patients with UC.
Although the data on the role of TNF in the pathogenesis of UC
have not been unequivocal, taken together they suggest that TNF
contributes to the mucosal damage and chronic inflammation
responsible for signs and symptoms of active UC (Table 2).
Current therapy options
The medical management of UC should be tailored to the disease
severity in every individual patient. Mild UC can usually be
managed with oral 5-aminosalicylates (mesalamine or
sulfasalazine). Since recent evidence suggests that 
5-aminosalicylates have a dose-dependent effect in UC above a
daily dose of 2 g, higher doses of these compounds are generally
used because they are well tolerated. For patients with moderate
disease (interfering with activities of daily life) refractory to
medical therapy, oral systemic steroids (at an initial dose of 40 mg
of prednisolone equivalent) have been proven to induce clinical
improvement and remission. However, systemic steroids have a
high burden of side effects when used long term and are only
used in courses of 3 to 4 months. Steroid-dependent patients
(those not being able to taper steroid therapy or needing several
courses of systemic steroids within 1 year) are therefore a key
target for drug development in UC. Patients who have achieved a
steroid-induced remission can return to 5-aminosalicylate
maintenance or start antimetabolite therapy (e.g. methotrexate).
Patients who have not responded to a 2- to 4-week course of oral
systemic steroids (at an initial dose of 40 mg prednisolone
equivalent or higher) are usually considered to fail oral steroids
(steroid-refractory) and need other treatment options.
Rectal therapy
Rectal therapy with 5-aminosalicylates offers clinical benefit for
fast relief of symptoms and increases disease remission and
Evidence Reference
Increase in mucosal TNF immunoreactive
cells
Murch et al. 1993
Increased TNF levels in mucosa, serum,
and stools
Murch et al. 1993; Casellas et
al. 1994; Komatsu et al. 2001
Stool TNF levels specifically increased in
endoscopically active UC
Casellas et al. 1994
Imbalance favoring TNF over neutralizing
soluble TNF receptors
Noguchi et al. 1998
Specific increase in TNF-activating
enzyme 
Brynskow et al. 2002
TNF, tumor necrosis factor; UC, ulcerative colitis.
Table 2 | Preclinical evidence supporting use of infliximab in
ulcerative colitis patientsendoscopic healing. Ambulatory patients with moderate disease
who continue to have symptoms of left-sided disease despite an
adequate course of oral mesalamine may benefit from rectal
mesalamine and/or rectally administered topical steroids to
alleviate their urgency and rectal blood loss. Rectal mesalamine at
a once-daily dose of 1 to 4 g is superior to rectal steroids for
treating distal disease and should always be considered as the
first option (Marshall & Irvine 1997). Rectal mesalamine therapy
also results in a more rapid and better disease control in patients
with extensive disease (Marteau et al. 2005).
Immunosuppressives 
The purine analogs azathioprine and 6-mercaptopurine have a
steroid-sparing effect in patients with UC responding to
corticosteroids but are not a treatment option for patients failing
these agents since they require 2 to 4 months of therapy at
adequate doses to produce a clinical effect. The folate antagonist
methotrexate has not proven to be efficacious in a randomized
trial to treat patients with moderately active steroid-refractory UC.
Recently, evidence from an uncontrolled open-label trial has
suggested a role for oral methotrexate in the treatment of
moderate UC (Cummings et al. 2005), but patients should know
that a 6- to 8-week lag phase is to be expected before this
treatment is efficacious. 
Oral cyclosporine at a starting dose of 5 mg/kg with subsequent
adjustment of trough levels to therapeutic ranges has been
proposed to treat patients with refractory UC based on results in
open-label studies (Actis et al. 1999; Navazo et al. 2001). The
other calcineurin inhibitor used in solid organ transplantation,
tacrolimus, given at an initial dose of 0.1 mg/kg has also been
reported in open-label trials to be efficacious in this setting
(Fellermann et al. 2002; Baumgart et al. 2006), given for a median
of 2 years in one of the patient cohorts (Baumgart et al. 2006).
Recently, a placebo-controlled Japanese study confirmed the
efficacy of high-dose tacrolimus in active colitis, with controlled
dosing to give a trough level of 10–15 ng/mL (Ogata et al. 2006).
However, both cyclosporine and tacrolimus are considered
nephrotoxic when used long term at these dose levels and
attempts to interrupt treatment after a period of 3 months is
usually made. Given the current evidence and the lack of long-
term safety data, oral tacrolimus and cyclosporine should be
regarded as “bridge” therapy, since azathioprine typically has a
delayed onset of action and an induction agent is needed to cover
the first 3 to 6 months.
Fulminant colitis
Only 15–20% of patients with UC will ever experience an attack
of fulminant colitis requiring in-hospital management (Edwards &
Truelove 1963). Patients with pancolitis appear to be predisposed
to severe flares. Fulminant UC is a serious, potentially life-
threatening condition and hospitalization should be considered in
all patients with severe attacks. Even if patients have been treated
with oral corticosteroids for the ongoing flare, intravenous
corticosteroids at a dose equivalent to prednisolone 60 mg should
be considered. Pioneering studies by Truelove et al. have shown
that by applying this strategy, 64% of patients will enter clinical
remission and only 23% require total proctocolectomy (Truelove
et al. 1978). Regardless of the treatment strategy these patients
require intensive attention by a surgical-medical team
experienced in dealing with severe colitis.
When patients fail 3 to 5 days of intravenous corticosteroids at
adequate doses, and continue to report frequent bloody diarrhea
with fever or high C-reactive protein levels, they should be
considered for total proctocolectomy or rescue medical treatment
(Travis et al. 1996). Complications such as toxic megacolon or
uncontrolled bleeding should favor surgical intervention.
Intravenous cyclosporine has been shown to be an effective
rescue therapy for severe UC attacks in three controlled trials
(Lichtiger et al. 1994; D’Haens et al. 2001; Van Assche et al. 2003).
In the trial by Lichtiger et al., nine out of 11 patients treated with
intravenous cyclosporine 4 mg/kg avoided colectomy, versus
none of the nine placebo-treated patients. Data from one single-
center controlled trial in 73 patients indicate that intravenous
cyclosporine 2 mg/kg per day as initial treatment may prove
effective for severe attacks of UC, although not all of these
patients were failing intravenous corticosteroids. When results
from controlled and uncontrolled trials are pooled, 76–85% of
patients will respond to intravenous cyclosporine and avoid
colectomy in the short term, with a median time to response of 
4 to 5 days (Van Assche et al. 2003). In responding patients,
initiation of oral cyclosporine therapy at 5–8 mg/kg divided into
two daily doses should be considered along with gradual steroid
tapering and initiation of azathioprine or 6-mercaptopurine.
However cyclosporine use in UC has been associated with
mortality, mostly as a result of opportunistic infections (Arts et al.
2004). Following initial response to cyclosporine for fulminant UC,
about 50% of patients avoid colectomy at 3 years (Cohen et al.
1999; Arts et al. 2004; Campbell et al. 2005; Moskovitz et al.
2006). Lower colectomy-free rates have been recently reported
with follow-up extending to 7 years (Moskovitz et al. 2006). The
patient population already failing adequate courses of
azathioprine or 6-mercaptopurine is most prone to colectomy
following initial response to cyclosporine (Moskovitz et al. 2006).
However, cyclosporine is only administered in 3-month courses to
patients with IBD. This probably explains why patients failing
azathioprine are more prone to early colectomy after initial
response to cyclosporine since no adequate exit strategy can be
provided. Oral cyclosporine and tacrolimus can be considered to
treat severe attacks of UC, but only retrospective uncontrolled
data are available for UC and the one controlled trial with oral
tacrolimus included ambulatory, less severe patients (Baumgart et
al. 2006; Ogata et al. 2006). Surgical proctocolectomy with ileo-
anal pouch anastomosis is a valid option for patients with
moderate to severe UC failing medical therapy. Patients should be
counseled about the option of surgery, and the short-term
complications and long-term outcomes of pouch surgery early in
the course of a severe flare of UC. The important need for
colectomy (at least 50% after 5 to 7 years) despite initial
successful medical management and the considerable toxicity of
cyclosporine therapy, emphasizes the active and early role of the
surgical team in the management of patients with UC. Early
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decision-making and timely colectomy can prevent surgical
complications and save patient lives, and should always 
be considered.
Unmet needs
The main unmet medical needs in UC are in patients with
moderate to severe disease failing 5-aminosalicylates and more
importantly corticosteroids, and also patients with corticosteroid-
dependent disease, who are at high risk of major side effects from
steroid therapy. In fulminant colitis, colectomy can be prevented
in the short term by intravenous corticosteroids, and by
cyclosporine in steroid-refractory patients, but long-term disease
control and salvage from colectomy is substantially reduced
despite the association of antimetabolite therapy. More
specifically, in patients failing adequate therapy with azathioprine
or 6-mercaptopurine, steroids and cyclosporine are of limited
value since they offer no long-term perspective. Also surgical
proctocolectomy, although a good solution for patients with
intractable disease or neoplasia, has several limitations including
pouchitis, postoperative obstruction, frequent stools, and
reduced female fecundity. Complications occur only in a small
proportion of patients, but cannot be predicted prior to 
the procedure. 
Therapeutic potential can therefore be expected from therapies
that meet all or most of the following aims:
• Induction and maintenance of symptomatic remission in a high
proportion of patients
• Sparing of corticosteroids
• Induction of endoscopic mucosal healing
• Prevention of surgery and avoidance of surgical complications if
colectomy is needed
• Long-term, highly beneficial benefit-to-risk ratio, including the
risk of colonic dysplasia.
In an attempt to address these needs and utilize the role of TNF
in UC pathogenesis, a number of anti-TNF agents have been
investigated. 
CDP-571 is a humanized, anti-TNF, IgG4 antibody that has been
evaluated in an open-label trial, and shows some improvement in
clinical scores although the effect was short-lived (Evans et al.
1997). A total of 15 patients with mild to moderate, mostly left-
sided disease were included. In these patients a significant
reduction in the mean Powell-Tuck scores was observed as soon
as 1 week after infusion of CDP-571 at 5 mg/kg, although the
endoscopic scores did not improve. The development of 
CDP-571 has been halted. 
RDP58 has been rationally designed to block the translation of
several cytokines such as TNF, IL-2, and IL-12. It is an interesting
small molecule that inhibits the production of several cytokines
including TNF at a posttranscriptional level and has been studied
in patients with moderately active UC. In a randomized trial
patients received placebo, or RDP58 100, 200, or 300 mg daily for
4 weeks (Travis et al. 2003). Both higher doses resulted in high
clinical remission rates (72% and 70% vs 40% in placebo-treated
patients). Also, histologic scores decreased more in RDP58-
treated patients. In this trial the placebo remission rate of 40%
was exceptionally high. Nevertheless, the drug appeared to be
safe and is appealing due to its oral route of administration and its
very low absorption. This low systemic bioavailability could have
favorable implications for the side effect profile.
Infliximab has been investigated in patients with UC, and forms
the focus of this review.
Clinical evidence for the use of infliximab in UC
Infliximab in adult UC
Open-label studies
The first reports on the use of the chimeric, humanized, anti-TNF,
IgG1 antibody infliximab in Crohn’s disease date back to 1995
and the compound has changed the treatment paradigm for this
illness. In UC, infliximab has been evaluated initially in several
open-label trials for refractory, moderate to severe disease. The
open-label trial experience with infliximab treatment for
moderately to severely active UC has generated conflicting
results to say the least (Table 3). Differences in patient populations
and the lack of strict diagnostic criteria at baseline only partially
account for this discrepancy. Differences in clinical scores used to
evaluate disease and in study endpoints (response vs remission)
are also only part of the explanation. As suggested in several
editorials, a strong placebo response for patients receiving an
intravenous treatment with proven high efficacy in Crohn’s
disease may have influenced the judgment of both patients and
investigators (Rutgeerts 2002; Cohen 2003).
A US, multicenter, open-label trial involving 27 patients (mostly
outpatients despite 89% having severe disease) investigated one
to three infusions of infliximab 5 mg/kg (Chey et al. 2001).
Remission was observed in 44% of patients and another 
six patients (22%) had a partial response. The median time to
response was 4 days and the median response duration 8 weeks.
Most nonresponding patients underwent colectomy. Interestingly,
steroid-refractory patients were less likely to respond than those
responding but relapsing during steroid tapering (33% vs 83%). 
Subsequently, several papers describing open-label trial
experience with infliximab were published. These trials have
generated opposing data on putative efficacy but no important
safety concerns have arisen. Bermejo et al. (2004) reported on the
use of infliximab in seven patients with disease refractory to
standard treatment. Of the six patients with steroid-dependent
disease, five (83%) responded both clinically and endoscopically.
Similarly, Kohn et al. (2002) reported on the success of infliximab
treatment in 13 patients admitted to a Turin academic hospital.
The retrospective analysis showed that clinical response was
obtained in 77% of infliximab-treated patients. A similar highclinical response rate in all six steroid-refractory patients treated
with intravenous infliximab has also been observed (Kaser et al.
2001). In contrast, Actis et al. (2002) showed a short-term
colectomy rate of 50% and a sustained response rate of only
25% in eight steroid-refractory patients treated with infliximab in
an open-label study. 
Level 2 evidence
These conflicting results achieved in open-label studies needed
to be challenged or confirmed in controlled studies. In 2003 the
results of a European, double-blind, randomized, controlled trial
with infliximab in steroid-resistant UC were published. This trial
enrolled 43 patients with active UC colitis resistant to oral
glucocorticosteroids (prednisolone ≥30 mg) (Probert et al. 2003).
Endoscopically active disease was present in all subjects at
inclusion. The Barron endoscopic score was used in this trial
which includes roughly the same criteria as more recently
developed scores (e.g. Mayo score, mentioned below). Mucosal
friability, erosions and ulcers, and fading of the vascular pattern
constitute the key criteria of most of these endoscopic scores. 
Patients were treated at weeks 0 and 2 with intravenous infliximab
5 mg/kg or placebo. At 6 weeks no difference in clinical remission
was observed between infliximab- and placebo-treated patients
(39% vs 30%). Also, the median improvement in the Barron
endoscopic activity score or the proportion of patients achieving
a score of 0 (endoscopic remission) was not different between
both groups (endoscopic remission 26% with infliximab vs 30%
with placebo). Patients were offered open-label intravenous
infliximab 10 mg/kg once and every 8 weeks thereafter if they did
not respond after 6 weeks, but the investigators were not
unblinded at this time point. Of the patients treated in this open-
label phase with infliximab, remission was achieved in 27% (3/11)
and 11% (1/9) of the original infliximab and the placebo groups,
respectively. No differences in the occurrence of serious adverse
events were noted and one patient in the placebo group had a
colectomy during the intervention period. 
Two large multicenter trials sufficiently powered to assess the true
therapeutic potential of infliximab in active, moderate to severe
UC have now been published (Rutgeerts et al. 2005). The Active
Colitis Trials, ACT-1 and ACT-2, enrolled 728 patients in 
171 centers worldwide. Each of the trials recruited patients with
clinically and endoscopically active disease. Patients were
randomized to receive infliximab 5 mg/kg, infliximab 10 mg/kg, or
placebo at week 0, 2, and 6 and than every 8 weeks thereafter for
22 weeks (ACT-1) or 46 weeks (ACT-2) in total. Apart from the
duration of treatment, the main difference between the two trials
was the fact that patients in ACT-2 were allowed to fail only
mesalamine whereas in ACT-1 only patients failing steroids and/or
purine analogs were eligible. All these drugs were continued for
the entire treatment phase of the two trials, except for steroids,
which were tapered from week 8. Efficacy assessment was based
on an intention-to-treat analysis and the primary endpoint was
clinical response at week 8 based on the Mayo disease activity
score (Schroeder et al. 1987). This score has been developed to
assess the efficacy of mesalamine and encompasses criteria of
stool frequency, rectal bleeding, findings at endoscopy, and
physician’s global assessment (Table 4). Again, the clinical criteria
used in the Mayo score are based on the clinical activity index
developed earlier and used in other trials with infliximab in UC.
The score can vary between 0 and 12, and patients with scores of
6 to 10 inclusive were eligible. Endoscopic activity of at least 2
(loss of vascular pattern and at least mucosal erosions) on the
Mayo scale was also a necessary inclusion criterion. The primary
endpoint of clinical response was defined as a decrease of at
least 3 points and at least 30% in the total Mayo score.
Secondary endpoints were clinical remission (total Mayo score of
2 points or lower with a maximum of 1 in any of the subscores)
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Design No. of
patients
Baseline steroid use Key outcomes Reference
Placebo controlled 43 All patients steroid refractory Infliximab not superior to placebo Probert et al. 2003 
Placebo controlled 45 All patients i.v. steroid refractory Infliximab superior to placebo Järnerot et al. 2005
Placebo controlled 728 30% steroid refractory Infliximab (5 and 10 mg/kg) superior to placebo Rutgeerts et al. 2005
Active comparator, open label 20 Steroid-refractory patients excluded Efficacy comparable to oral steroids Armuzzi et al. 2004 
Active comparator, open label 13 Steroid-refractory patients excluded Efficacy comparable to oral steroids Ochsenkühn et al. 2003 
Placebo controlled, early termination 11 All patients i.v. steroid refractory 50% infliximab response, 0% placebo response Sands et al. 2001 
Open label, retrospective 16 All patients steroid refractory 88% response Chey et al. 2001 
Open label 27 Improved response rates in steroid-
responsive disease
66% response, 44% remission Su et al. 2002 
Open label, retrospective 7 6/7 steroid responsive 5/6 response (all steroid responsive) Bermejo et al. 2004 
Open label, retrospective 13 All patients i.v. steroid refractory 77% response rate Kohn et al. 2002 
Open label, retrospective 8 All patients steroid refractory 50% immediate colectomy, 4/6 response Actis et al. 2002 
Open label, retrospective 6 All patients steroid refractory 6/6 improvement, 4/6 remission  Kaser et al. 2001 
i.v., intravenous.
Table 3 | Summary of outcomes with infliximab in adult ulcerative colitis patients157
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and endoscopic healing (endoscopic score of 0 or 1). Baseline
characteristics of the patients in both ACT-1 and ACT-2 were very
similar in both trials. More than half of patients (56%) entered the
trials on steroid therapy (60% on prednisolone <20 mg) and less
than half were on immunosuppressives (46%). Early
discontinuation, mostly due to aggravation of colitis, occurred
twice as frequently in placebo-treated patients. 
In ACT-1, the clinical response at week 8 (following a three-dose
induction with infliximab) was 69% and 62% for patients receiving
infliximab 5 and 10 mg/kg, respectively, compared with 37% of
those receiving placebo (P<0.005 for both comparisons). In 
ACT-2, very similar results were obtained, with 65% and 69% of
patients receiving infliximab 5 and 10 mg/kg, respectively,
achieving a clinical response at week 8, compared with 26% in
the placebo group (P<0.001 for both comparisons). In both
studies, the proportion of patients who achieved clinical response
at weeks 8, 30, or 54 (ACT-1) or clinical remission at weeks 30 or
54 (ACT-1) was several-fold higher among infliximab-treated
patients than placebo-treated patients. At week 54, 16% of
patients on placebo, 35% on infliximab 5 mg/kg, and 34% on 
10 mg/kg were in remission (P=0.001 for both comparisons).
Sustained remission at week 8, 30, and 54 was observed in fewer
patients, but again significant differences were observed between
the placebo- (7%) and infliximab-treated groups (20%) in ACT-1.
Endoscopic mucosal healing was also significantly more frequent
in infliximab recipients. At week 8, approximately 30% of
placebo-treated compared with 60% of infliximab-treated
patients had complete mucosal healing or only mild lesions, and
this difference remained significant at week 30 in both ACT-1 and
ACT-2, and at 54 weeks in ACT-1.
A recent Cochrane analysis concluded that there is level 1
evidence to support the efficacy of infliximab in UC based mainly
on the ACT-1 and ACT-2 trial results (Lawson et al. 2006). The
relative risk versus placebo to be in clinical remission with
intravenous infliximab 5 mg/kg at weeks 0, 2, and 6 was 3.2 [95%
confidence interval (CI) 2.18, 4.76].
Furthermore, infliximab produced clear steroid-sparing effects. In
ACT-1, the median prednisolone dose decreased from 20 mg at
baseline to 8.5 mg at week 54. Despite the steroid-sparing
potential, however, only 21% of patients were in clinical remission
and off steroids at 1 year. This indicates that one in three patients
in remission still had some degree of steroid therapy, but the
figures compare well with data observed in Crohn’s disease
maintenance trials with anti-TNF agents (Hanauer et al. 2002). As
in Crohn’s disease, the 10 mg/kg dose appeared to offer no
additional clinical benefit over the 5 mg/kg dose of infliximab. 
Evidence from active comparator trials 
Recently, two small, open-label, randomized trials were initiated
to explore the efficacy of infliximab compared with oral
corticosteroids in patients with active disease not failing steroids.
A first study enrolled 20 patients with moderate to severe (Mayo
score ≥6) disease to receive infliximab 5 mg/kg intravenously at 0,
2, and 6 weeks and every 8 weeks thereafter, or corticosteroids
0.7–1 mg/kg for 1 week followed by gradual tapering (Armuzzi et
al. 2004). Preliminary results showed that all patients (10/10) in
both groups achieved clinical remission. After a median of 
10 months’ follow-up, 9/10 of the infliximab group and 8/10 of
those on corticosteroids were still in clinical remission. Patients
who relapsed were successfully treated either with infliximab at
shorter intervals of 6 to 4 weeks (initial infliximab group) or with
infliximab at 0, 2, and 6 weeks (steroid group). 
Ochsenkühn et al. (2003) also reported preliminary data from an
open-label, randomized trial comparing intravenous infliximab 
5 mg/kg given at week 0, 2, and 6 (n=6) with high-dose
prednisolone 1.5 mg/kg (n=7) for inducing remission in active UC
not failing steroids. Clinical response was achieved in 5/6 of the
infliximab- and in 6/7 steroid-treated patients. 
Infliximab in fulminant colitis
An initial report by Chey et al. (2001) showed an extremely high
efficacy in 16 patients with severe disease. In seven of these
patients infliximab was used as a rescue therapy to avoid
colectomy. After a single infliximab 5 mg/kg infusion, 88% of
patients responded with a marked clinical and endoscopic
improvement. Successful steroid tapering was possible in most
Score Description
Stool frequency
0 Normal number of stools for this patient
1 1–2 stools more than normal
2 3–4 stools more than normal
3 5 or more stools than normal
Rectal bleedinga
0 No blood seen
1 Streaks of blood with stool less than half of the time
2 Obvious blood with stool most of the time
3 Blood alone passed
Mucosal appearance
0 Normal or inactive disease
1 Mild disease (erythema, decreased vascular pattern, 
mild friability)
2 Moderate disease (marked erythema, absent vascular
pattern, friability, erosions)






aMost severe bleeding of the day determines the score.
Table 4 | Mayo scoring system for active ulcerative colitis
(reproduced with permission from Schroeder et al. 
N Engl J Med. 1987;317:1625–1629. 
Copyright © 1987 Massachusetts Medical Society. 
All rights reserved.)patients and sustained clinical improvement was observed for at
least 4 months. 
Consecutively, a placebo-controlled, multicenter trial was
terminated prematurely due to slow patient enrollment. The study
was scheduled to enroll 60 patients in severe, active, steroid-
refractory UC, but eventually enrolled just 11 patients; eight in the
infliximab group (5, 10, or 20 mg/kg for one infusion) and three in
the placebo group (Sands et al. 2001). Four patients treated with
infliximab improved after 2 weeks versus none receiving placebo.
The precise implication of these data is hard to define due to the
limited size of the patient population. 
More recently the results of a Scandinavian placebo-controlled
trial confirmed the initial findings. In this trial, patients with
moderate to severe UC failing to respond to hospital treatment
with intravenous steroids (betamethasone 4 mg/day) were
randomized to receive infliximab 5 mg/kg in one infusion or
placebo (Järnerot et al. 2005). Patients were eligible either
because of fulminant colitis [assessed with the Sweden index
(Seo et al. 2002)] at day 4 after starting intravenous steroids, or
because they had more moderate disease activity but failed to
improve from day 4 until day 8. Mesalamine therapy was started
or continued in all patients and azathioprine was initiated at the
discretion of the investigator. In total 45 patients were included, of
whom 24 received infliximab, over a period of 3.5 years. Sixty-two
percent of patients in both groups were included on the basis of
the fulminant colitis index in both groups. Of note, more patients
in the placebo group were experiencing their first attack of UC
(43% vs 12% in the infliximab group). 
The primary endpoint of the trial was defined as colectomy or
death within 90 days from baseline. Significantly more patients in
the placebo group met this endpoint (67% vs 29%, P<0.02; odds
ratio 4.9; 95% CI 1.4, 17). The cumulative proportion of patients
not needing colectomy after 90 days was 71% in the infliximab
group versus 33% in the placebo group (P<0.05). Interestingly,
the difference in colectomy rates between the two groups was not
significant for the patient groups recruited on the basis of
fulminant disease activity at day 4, but only for those with more
moderate disease at that time point. Severe endoscopic lesions at
baseline, however, were not associated with poor prognosis. 
In summary, this trial provides evidence of the potential of
infliximab to prevent colectomy in hospitalized patients with
steroid-refractory UC, but long-term outcome data on the patient
population included in this trial are needed to define the precise
role of infliximab in the setting of fulminant colitis.
Safety of long-term infliximab therapy
Biologic agents are selective and powerful therapies for patients
with IBD. Although the experience with infliximab has shown a
beneficial benefit-to-risk ratio, some specific complications need
to be addressed (Table 5).
The chimeric nature of the monoclonal antibody infliximab gives
rise to antibodies to infliximab (ATIs) in humans. ATIs are
associated with acute infusion reactions and loss of response,
and with delayed hypersensitivity reactions and secondary loss
of response. Acute infusion reactions are manifested by
shortness of breath, chest pain, palpitations, flushing,
headache, and sometimes urticaria and hypotension. They are
in most cases easily managed with slowing of the infusion and
administration of antihistamines and/or hydrocortisone. Patients
who have experienced acute infusion reactions should receive
prophylactic hydrocortisone before subsequent infusions. The
delayed infusion reactions or serum sickness-like reactions
occur typically 4–9 days after an infusion and are characterized
by arthralgias (which may include unusual locations such as the
jaw), back pain, myalgias, fever, skin rash, and leukocytosis.
These delayed reactions need management with high doses of
steroids for 4–7 days. 
The risk of serious infections, particularly with intracellular
pathogens such as Myobacterium tuberculosis is increased in
infliximab-treated patients and has been related to mortality. In
patients with Crohn’s disease and rheumatoid arthritis, no clear
increase in lymphoma incidence has been found in controlled
clinical trials. A recent meta analysis of clinical trials with
infliximab and adalimumab for rheumatoid arthritis suggested
an increased risk of malignancy in patients receiving higher 
(≥6 mg/kg) doses of infliximab (odds ratio 4.3; 95% CI 1.6, 11.8)
(Bongartz et al. 2005). For patients treated with infliximab in
rheumatoid arthritis, the number needed to harm was 59 for
serious infections, and 154 for malignancy. From clinical trials
and from postmarketing surveillance, no increased risk of
malignancy has become apparent with the use of infliximab
(Biancone et al. 2006; Lichtenstein et al. 2006). Nevertheless,
infliximab in combination with azathioprine has been associated
with rare cases of gamma/delta T-cell hepatosplenic lymphoma
in 10 young patients, nine of whom had Crohn’s disease, and
one with unclassified colitis (Anon. 2007). Although it is
impossible to define the relative role of both drugs in these
lymphoma cases, they illustrate the need for postmarketing
safety surveillance. In this respect, the North American TREAT
registry has not revealed an increased risk for malignancies
related to the use of infliximab in patients with Crohn’s disease
thus far (Lichtenstein et al. 2006). An in-silico model of the
benefit-to-risk ratio with the use of infliximab based on
experience in clinical trials and in large patient cohorts came up
with a beneficial effect of an infliximab-based strategy over non-
infliximab-based management. More specifically, surgery-free
remission was clearly increased in the putative infliximab-
treated patient group. However, this came with the price of an
increased mortality and lymphoma risk (Siegel et al. 2006). 
In the ACT-1 and ACT-2 trials the total number of adverse events
and the proportion of patients with adverse events was similar
in placebo- and infliximab-treated patients (Rutgeerts et al.
2005). The proportion of patients with a serious adverse event or
with an infectious event was also similar in the three groups, but
in ACT-1 significantly more patients in the combined infliximab
group had an infectious event necessitating antibiotic treatment.
In both studies combined, four neoplasias were found in 
the infliximab-treated patients versus one in the placebo 
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group. Neurologic events occurred in three infliximab recipients
and one patient exposed to infliximab developed drug-
induced lupus. 
Patients with UC resistant to intravenous steroids enrolled in the
Scandinavian controlled trial had no specific safety issues when
exposed to infliximab (Järnerot et al. 2005). Of note, two
patients in the placebo group had a septic complication after
colectomy, which confirms the association of postoperative
complications with high-dose steroids rather than with
infliximab or purine analogs. 
UC carries a limited but intrinsic risk of colorectal cancer, which
is thought to develop from dysplasia originating in chronically
inflamed mucosa. Since one of the aims of medical therapies
such as anti-TNF agents is to prevent colectomy, particularly in
patients with fulminant disease, saving the colon may expose
patients to a higher dysplasia risk in the long term. On the other
hand, mucosal healing and regression of inflammation, as has
been shown with anti-TNF therapy, should counterbalance this
increased risk of neoplasia (Rutter et al. 2004, 2006). Also, the
risk of colorectal cancer in patients with longstanding UC
reported in recent patient cohorts is considerably lower than
what has been reported before (Jess et al. 2006). This
observation cannot be explained by increased colectomy rates,
but the exact role of improved disease control with medical
therapy in the apparent decrease of the cancer risk is also not
clear. The dysplasia and rectal cancer cases in the ACT trials
both occurred in infliximab-treated patients, but the trials were
not powered to study the influence of infliximab on rare events
such as dysplasia. In patients with fulminant colitis, particularly
those with pancolitis, the risk of developing cancer when the
colon is saved and preserved long term, has not been
specifically studied and cannot be weighed against surgical
morbidity with colectomy. As long as this question remains
unresolved, it appears prudent to apply surveillance programs
to patients with longstanding UC controlled with any form of
medical therapy, including anti-TNF antibodies.
Resource utilization
No published data on direct assessments of resource 
utilization with the use of infliximab in UC are known to the
authors. However, the ACT-1 and ACT-2 trials show that
scheduled maintenance therapy with infliximab for 1 year
reduces the need for hospitalization (Rutgeerts et al. 
2005). Hospitalization and surgery contribute heavily to the 
cost of treatment in these patients. There appear to be no 
long-term data on colectomy rates in patients successfully
treated with infliximab. Total colectomy abolishes the need 
for further treatment in UC patients and most patients have 
a good quality of life after colectomy. Since biologic agents
such as infliximab weigh significantly on the direct drug 
cost to induce remission in UC patients, further studies
exploring prevention of hospitalization and colectomy, of the
ability to work, and of added quality-adjusted life-years are
crucial. These outcomes have been achieved with infliximab in
Crohn’s disease, but specific data are needed in patients 
with UC. 
Dosage, administration, and fomulations
The label for infliximab for use in patients with moderate to
severe UC granted by both the European Medicines Agency
and the Food and Drug Administration allows both induction
and maintenance therapy in patients with treatment-refractory
active colitis. Induction therapy consists of intravenous
infliximab 5 mg/kg at week 0, 2, and 6. In scheduled
maintenance therapy, infliximab is administered intravenously
at a dose of 5 mg/kg every 8 weeks. Studies in Crohn’s disease
have shown that scheduled maintenance is superior to periodic
therapy during disease flare in the prevention of
immunogenicity to the chimeric antibody, and is considered the
optimal strategy (Hanauer et al. 2002; Rutgeerts et al. 2004;
Sands et al. 2004). However, no direct comparison between the
two modalities of treating patients long term has been
performed in UC. 
Disease mechanism Clinical equivalent Drugs observed with  Preventive strategies
Immunosuppression Infections, malignancy Infliximab
Adalimumab, certolizumab-pegol
Natalizumab
Screening for latent infections
Physicians’ awareness





Humanization of therapeutic Ab
Systematic maintenance treatment
Concomitant immunomodulators/steroids
Induction of autoantibodies Drug-induced lupus arthralgias Infliximab
Demyelinization neurotoxicity Central/peripheral neuropathy
Optic neuritis
Infliximab Screening past history
Physicians’ awareness
Toxicity in diseased cardiac muscle Progressive cardiac failure Infliximab Contraindicated in NYHA grade III–IV cardiac failure 
aOnly infliximab has been approved by the Food and Drug Administration and European Medicines Agency for use in ulcerative colitis. Data for this agent are deducted from clinical trial 
and postmarketing experience. The risk of malignancy in patients treated with biologic agents is still debated and so far no increase over the incidence in the general population has been
formally documented.
NYHA, New York Heart Association.
Table 5 | Complications associated with the use of biologic agents in inflammatory bowel diseasesaPlace in therapy
Although the clinical development of anti-TNF agents in Crohn’s
disease has clearly outpaced the progress in UC, a lot of progress
has been achieved in recent years. The role of anti-TNF in the
effector phase of the inflammatory reaction in both UC and Crohn’s
disease provides a scientific rationale to investigate the therapeutic
potential of anti-TNF agents in UC. However, the initial data
obtained in retrospective and prospective open-label trials yielded
conflicting results. More recently, data from two large, controlled
trials with infliximab in patients with moderate to severe UC has
clearly shown clinical efficacy of the antibody to induce clinical
response and remission short term and long term, to induce and
maintain mucosal healing, and to spare steroids. Moreover, the first
fully conducted, randomized controlled trial in patients with
fulminant steroid-refractory UC has demonstrated that infliximab is
efficacious at inducing clinical improvement and at preventing
colectomy. Outstanding issues in patients with fulminant colitis are
associated with the relative role of infliximab and cyclosporine in
medical management. In general, it appears that the same rules for
timing of infliximab and cyclosporine therapy should be followed
(initiation after 3–5 days of unsuccessful intravenous steroid
therapy). No trials comparing the relative efficacy of both drugs are
available at present. Also, data on the use of infliximab in patients
failing cyclosporine or vice versa are extremely scant. Theoretical
concerns have arisen about the long half-life of a monoclonal
antibody in patients considered for additional immunosuppressive
therapy, but prospective safety data are lacking.
Since the patient population included in the large ACT-1 and 
ACT-2 trial was quite heterogeneous, a more broad population may
be eligible for treatment. It is clear that 5-aminosalicylates will
remain first-line therapy for mild to moderate UC. Patients with
moderate disease failing oral corticosteroids, who are dependent
on corticosteroids, or who are considered for their second course
of steroids within 6 months after failing the previous course should
be considered for infliximab therapy. Previous antimetabolite
therapy should not prevent infliximab therapy since in ACT-1 and
ACT-2 such patients were clearly responding. Although not all
patients achieve clinical remission with infliximab, it should
influence clinical practice particularly in patients with refractory
disease. No new safety issues specific for UC patients have arisen
from the combined experience reported in the literature, but the
side effect profile of anti-TNF agents should be known to every
clinician using this potent therapy.
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